CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new cancer therapies by targeting the Polycomb repressive complex 2 (PRC2) to reactivate silenced tumor suppressor genes. By identifying proteins that can rewire PRC2's function, the project aims to create compounds that enhance gene expression and inhibit cancer cell proliferation.
Polycomb repressive complex 2 (PRC2), which incorporates repressive methyl-lysine marks on histone H3 to facilitate global transcriptional repression, is an integral epigenetic modifier in normal development.
Components of this complex, especially EZH2, are hyperactive or overexpressed in a broad range of cancers, resulting in excessive silencing of tumor suppressor genes (TSGs).
Moreover, cancers with defects in the SWI/SNF complex, the most frequently mutated chromatin regulatory complex in ca…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
